CRIS Current Research Information System

RASCHI, EMANUEL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.091
AS - Asia 11.578
EU - Europa 7.449
Continente sconosciuto - Info sul continente non disponibili 741
SA - Sud America 729
AF - Africa 627
OC - Oceania 44
Totale 33.259
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.757
SG - Singapore 3.101
CN - Cina 2.801
VN - Vietnam 2.687
IT - Italia 2.085
GB - Regno Unito 1.497
HK - Hong Kong 1.043
DE - Germania 873
SE - Svezia 558
BR - Brasile 547
IN - India 511
FR - Francia 453
RU - Federazione Russa 349
NL - Olanda 315
KR - Corea 298
BD - Bangladesh 297
FI - Finlandia 261
IE - Irlanda 237
JP - Giappone 231
CI - Costa d'Avorio 203
CA - Canada 182
UA - Ucraina 161
TG - Togo 160
ZA - Sudafrica 135
ID - Indonesia 87
AT - Austria 81
EE - Estonia 81
BG - Bulgaria 80
AR - Argentina 73
PH - Filippine 71
TR - Turchia 65
ES - Italia 63
PL - Polonia 63
JO - Giordania 61
TH - Thailandia 59
MX - Messico 58
CH - Svizzera 57
BE - Belgio 54
TW - Taiwan 41
IQ - Iraq 40
AU - Australia 35
PT - Portogallo 35
SA - Arabia Saudita 35
EC - Ecuador 30
UZ - Uzbekistan 29
PK - Pakistan 27
JM - Giamaica 26
SC - Seychelles 26
NG - Nigeria 24
CL - Cile 22
CO - Colombia 22
HR - Croazia 22
GR - Grecia 20
LT - Lituania 19
MY - Malesia 18
IL - Israele 15
KE - Kenya 15
CZ - Repubblica Ceca 14
EG - Egitto 13
RO - Romania 12
TN - Tunisia 12
CR - Costa Rica 11
VE - Venezuela 11
MA - Marocco 10
NI - Nicaragua 10
DK - Danimarca 9
DZ - Algeria 9
GT - Guatemala 9
HN - Honduras 9
NZ - Nuova Zelanda 9
PY - Paraguay 9
IR - Iran 8
PE - Perù 8
HU - Ungheria 7
LB - Libano 7
NP - Nepal 7
SK - Slovacchia (Repubblica Slovacca) 7
BA - Bosnia-Erzegovina 6
KZ - Kazakistan 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
GH - Ghana 5
OM - Oman 5
SI - Slovenia 5
ET - Etiopia 4
MD - Moldavia 4
MT - Malta 4
PR - Porto Rico 4
RS - Serbia 4
SM - San Marino 4
SV - El Salvador 4
AZ - Azerbaigian 3
CY - Cipro 3
DO - Repubblica Dominicana 3
EU - Europa 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AM - Armenia 2
BS - Bahamas 2
Totale 32.480
Salva come PNG Salva come JPEG
Città #
Singapore 2.145
Southend 1.209
Ashburn 1.179
Hong Kong 966
Fairfield 849
San Jose 759
Hefei 660
Chandler 651
Ho Chi Minh City 639
Bologna 536
Hanoi 498
Santa Clara 450
Dong Ket 391
Wilmington 390
Woodbridge 388
Council Bluffs 381
Seattle 375
Beijing 334
Houston 319
Princeton 318
Boardman 302
Cambridge 298
Los Angeles 276
Seoul 274
Ann Arbor 254
Dublin 231
Helsinki 218
Abidjan 203
Dallas 193
Lauterbourg 191
New York 177
Tokyo 173
Lomé 159
Milan 142
Redmond 140
Buffalo 111
Berlin 99
Westminster 99
Rome 94
The Dalles 94
London 89
Nanjing 88
São Paulo 85
Da Nang 80
Padova 80
Haiphong 79
Sofia 77
Frankfurt am Main 74
Redondo Beach 71
Florence 68
Turin 68
Saint Petersburg 66
Shanghai 66
Jacksonville 65
Jinan 64
Bengaluru 62
Amman 59
San Diego 59
Chicago 58
Munich 58
Jakarta 56
Guangzhou 55
Orem 54
Toronto 53
Falls Church 51
Shenyang 49
Vienna 49
Brussels 48
Bremen 46
Phoenix 43
San Francisco 43
Biên Hòa 42
Modena 42
Des Moines 41
Medford 39
Nuremberg 38
Amsterdam 37
Hebei 37
Bern 36
Hangzhou 36
Changsha 35
Tianjin 35
Nanchang 34
Montreal 33
Atlanta 32
Boydton 32
Warsaw 32
Paris 31
Johannesburg 30
Zhengzhou 30
Bangkok 28
Brooklyn 28
Mexico City 28
Shenzhen 28
Washington 28
Hải Dương 27
Jiaxing 26
Miami 26
Verona 26
Dearborn 25
Totale 20.070
Salva come PNG Salva come JPEG
Nome #
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 496
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 493
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 439
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 384
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 350
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals 338
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 327
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 310
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 293
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 282
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 281
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 276
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 263
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation 261
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 247
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 245
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 245
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 245
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 239
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 239
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 239
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 238
Advancements in drug development for diarrhea-predominant irritable bowel syndrome 238
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 235
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 235
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. 224
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 223
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure 221
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 220
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 217
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 214
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 213
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 209
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 208
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 205
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 203
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 203
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 202
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis 200
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 199
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 197
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies 195
Drug-induced Kounis syndrome: A matter of pharmacovigilance 194
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 193
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 193
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications 192
Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system 192
The interface of depression and diabetes: treatment considerations 188
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 188
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 188
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 187
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 187
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 186
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 186
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 185
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 184
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 184
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 184
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 180
New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research 177
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 177
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 175
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 174
The hERG K+ channel: target and antitarget strategies in drug development. 173
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 171
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 171
Attitudes, barriers, and facilitators toward tools supporting appropriate prescribing among healthcare professionals: a cross-sectional study 171
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 168
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 167
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 167
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 167
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology 167
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 166
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective 163
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 162
Use and Perception of Phytoestrogens in Postmenopausal Women: Result of a Questionnaire-Based Survey 161
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 160
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 157
Impact of notoriety bias on reporting of pancreatitis with antidiabetics: the case of exenatide 157
Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database 157
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety 157
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 157
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 156
Safety of Hydroxychloroquine: What a Dermatologist Should Know 155
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system 155
Apparato Gastroenterico 153
Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS 152
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality 152
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. 151
The beta3-adrenoceptor as a therapeutic target: current perspectives. 150
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 149
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 147
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. 147
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease 147
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 147
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 147
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 146
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline 145
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 145
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution 144
Totale 20.692
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.037
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 363
Totale 98.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.682 0 89 140 125 239 184 182 242 154 147 642 538
2022/20233.487 382 404 265 413 246 231 167 257 517 171 276 158
2023/20241.432 91 178 166 235 118 181 62 110 43 94 86 68
2024/20255.077 285 692 551 289 616 271 339 216 156 342 298 1.022
2025/202612.966 1.134 1.151 1.173 877 1.303 685 1.798 476 2.020 968 709 672
2026/20271.421 516 905 0 0 0 0 0 0 0 0 0 0
Totale 33.259